Uterine Leiomyosarcoma Management, Outcome, and Associated Molecular Biomarkers: A Single Institution’s Experience
Kristelle Lusby(The University of Texas MD Anderson Cancer Center), Raphael E. Pollock(The University of Texas MD Anderson Cancer Center), Tugce E. Dogan(The University of Texas MD Anderson Cancer Center), Ryan Lam(The University of Texas MD Anderson Cancer Center), Chiara Colombo(The University of Texas MD Anderson Cancer Center), Elizabeth G. Demicco(Harvard University), Chad J. Creighton(Baylor College of Medicine), Alexander J. Lazar(The University of Texas MD Anderson Cancer Center), Matthew L. Anderson(Institute for Molecular Medicine), Dina Lev(Assuta Medical Center), Kari J. Brewer Savannah(The University of Texas MD Anderson Cancer Center), Jason L. Hornick(Harvard University), Eric D. Young(The University of Texas MD Anderson Cancer Center), Markus PH. Ghadimi(Düsseldorf University Hospital), Yiqun Zhang(Baylor College of Medicine), Kelly K. Hunt(The University of Texas MD Anderson Cancer Center)
Cited by 78
Related Papers
UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses
|Neoplasia|2017|6.5k
UALCAN: An update to the integrated cancer data analysis platform
|Neoplasia|2022|2.5k
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
|Proceedings of the National Academy of Sciences|2009|1.4k
The 2019 World Health Organization classification of tumours of the breast
|Histopathology|2020|1.1k